The dark cloud of tariffs is pressing down! Barclays singled out the medical device industry in the US stock market as both the "pressure-resistant king" and the "hard-hit area".

Barclays PLC Sponsored ADR analyzed the impact of the Trump administration's new tariff policies on the medical device industry in a research report. The report indicates that Abbott Laboratories (ABT.US) and Baxter International Inc. (BAX.US) will be among the least affected companies, while Johnson & Johnson (JNJ.US) and Medtronic Plc (MDT.US) will be the most affected companies. Barclays analysts stated that among large medical technology companies, Abbott Laboratories, Baxter International Inc., Edwards Lifesciences (EW.US), and Intuitive Surgical, Inc. (ISRG.US) ("buy" rating), as well as Zimmer Biomet Holdings, Inc. (ZBH.US) ("sell" rating) are among the companies least affected by tariffs. Similarly, according to the analysts at this research brokerage firm, in the mid-cap sector, it seems that companies like Globus Medical (GMED.US), Alphatec (ATEC.US), and Tandem Diabetes Care (TNDM.US) are minimally affected by tariffs. Barclays analysts added that in contrast, several companies heavily reliant on overseas production to supply products sold in the US face significant tariff risks. These include Becton Dickinson (BDX.US), InMode (INMD.US), and Medtronic Plc ("buy" rating), as well as Insulet Corporation (PODD.US), Johnson & Johnson, and Bausch Health (BLCO.US) ("neutral" rating).